Investor Relations

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
 
natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

November 23, 2022
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
AUSTIN, Texas , Nov. 23, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman , chief executive officer, and Mike Brophy , chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
ctDNA reduction at week nine in patients treated with tebentafusp was associated with improved overall survival AUSTIN, Texas , Nov. 21, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine ,
November 15, 2022
Natera Announces Pricing of Follow-On Offering
AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share.
November 15, 2022
Natera Launches Proposed Follow-On Offering
AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a
November 8, 2022
Natera Reports Third Quarter 2022 Financial Results
AUSTIN, Texas , Nov. 8, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022 .     Recent Strategic and Financial Highlights Generated total revenues of $210.6 million in the third

Upcoming Events

Past events